Exelixis

Exelixis is a biopharmaceutical company based in the United States, with headquarters in South San Francisco, California. The company was founded on January 1, 1994 and is incorporated in Delaware. Exelixis is actively operating and has between 500 and 999 employees. The company's legal name is Exelixis, Inc. .

Exelixis operates in various industries, including healthcare, biomedical engineering, pharmaceutical industry, technology, biology, and biotechnology. The company is listed on the Nasdaq stock exchange under the ticker symbol EXEL.

Exelixis has been assigned 107 patents, showcasing its commitment to research and development in the biomedical and pharmaceutical fields.

The CEO of Exelixis is Michael M. Morrissey. The company's board of directors includes George Poste, Carl B. Feldbaum, Jack Wyszomierski, Michael M. Morrissey, Stelios Papadopoulos, and Maria C. Freire.

Exelixis can be contacted through their official website, http://exelixis.com, or their contact page, https://www.exelixis.com/contact-us/. The company's phone number is +16508377000, and their fax number is (650) 837-8300. Exelixis' full address is 1851 Harbor Bay Parkway, Alameda, CA 94502, USA.

Exelixis has a presence on various social media platforms, including Twitter (https://twitter.com/exelixisinc?lang=en) and Facebook (https://www.facebook.com/exelixisinc/). The company also has a LinkedIn profile (https://www.linkedin.com/company/8013/) and a Crunchbase profile (https://www.crunchbase.com/organization/exelixis).